Clinical Validation
Evora Evidence
Built on Research. Supported by Data.
Evora Diagnostics is built upon years of scientific research, clinical validation, and interdisciplinary collaboration.
Our technology platform has been developed through academic research, peer-reviewed publications, clinical studies, and ongoing validation efforts designed to support the future of rapid diagnostic testing.
A Strong Scientific Foundation
Overview
Evora Diagnostics originated from research conducted at UCLA through collaborations among the Electrical & Computer Engineering Department, the Bioengineering Department, and the California NanoSystems Institute (CNSI).
Over the course of development, our platform has been supported by scientific publications, patent activity, clinical studies, and extensive research funding focused on advancing rapid diagnostic technologies.
Clinical Validation
Evaluating Diagnostic Performance
Evora’s platform has undergone multiple stages of validation and testing as part of its ongoing development.
Validation Highlights:
- Multiple blinded validation studies completed
- Evaluation using multiple samples from Lyme Disease biobanks
- Evaluation using CDC Lyme disease repository samples
- Testing across serum and whole blood samples
- Ongoing clinical and analytical validation efforts
Performance Data
Accuracy & Reliability
In blinded validation studies using multiple samples from Lyme Disease biobanks, the platform demonstrated greater than 90% sensitivity and approximately 100% specificity.
Additional blinded evaluations using CDC Lyme disease repository samples demonstrated strong agreement with standard two-tier testing and successfully differentiated Lyme disease from look-alike conditions within the evaluated cohorts.
As development continues, Evora remains focused on rigorous validation and ongoing performance assessment.
How Evora Compares
Technology Validation
Years of Research and Development
Evora’s diagnostic platform is the result of years of scientific investigation into paper-based diagnostics, multiplexed biosensing, machine learning, and point-of-care testing technologies.
Research supporting the platform has contributed to advances in:
- Lyme disease diagnostics
- Tick-borne disease testing
- Artificial intelligence-driven diagnostics
- Point-of-care biosensing
- Multiplexed assay development
- Portable diagnostic platforms
IP portfolio
US Patent No. 12,013,395 (2018)
US Patent App. No. 63/730,460 (2019)
PCT/US20/34349 (2024)
PCT/US25/14220 (2025)
Intellectual Property
Protecting Innovation
Evora’s platform is supported by a growing intellectual property portfolio developed through years of research and innovation.
- Intellectual Property Highlights
- Multiple issued patents
- U.S. patent applications
- International patent filings
- Ongoing technology development and protection efforts
Regulatory Progress
Advancing Toward Clinical Deployment
Evora continues to advance clinical validation, regulatory planning, and commercialization activities designed to support future deployment of its diagnostic technologies.
Current efforts include:
- Clinical validation studies
- Analytical validation
- Regulatory planning
- FDA engagement preparation
- Expansion of disease-specific diagnostic programs
Because diagnostic technologies require extensive validation and regulatory review, all product candidates remain subject to development, testing, and applicable regulatory approvals.
Milestones
Development Progress
Achieved
UCLA research foundation established
Core technology development completed
Multiple validation studies completed
Scientific publications published
Patent portfolio established
Expansion opportunities identified across multiple disease areas
In Progress
Clinical validation studies
Regulatory preparation
Platform expansion initiatives
Commercialization planning
Strategic partnerships
Publications
Peer-reviewed Research
The scientific foundation supporting Evora’s technology has been published in leading journals across diagnostics, bioengineering, and digital health.
Paper-based multiplexed vertical flow assay for point-of-care testing
Point-of-Care Serodiagnostic Test for Early-Stage Lyme Disease Using a Multiplexed Paper-Based Immunoassay and Machine Learning
Deep learning-enabled point-of-care sensing using multiplexed paper-based sensors
Deep Learning-Enabled Multiplexed Point-of-Care Sensor using a Paper-Based Fluorescence Vertical Flow Assay
A Paper-Based Multiplexed Serological Test to Monitor Immunity against SARS-COV-2 Using Machine Learning
Rapid single-tier serodiagnosis of Lyme disease
Deep Learning-Enhanced Paper-Based Vertical Flow Assay for High-Sensitivity Troponin Detection Using Nanoparticle Amplification
Deep Learning-Enhanced Chemiluminescence Vertical Flow Assay for High-Sensitivity Cardiac Troponin I Testing
Paper-Based Vertical Flow Assays for in Vitro Diagnostics and Environmental Monitoring
Rapid Point-of-Care Inflammatory Cytokine Monitoring during Normothermic Liver Perfusion via a Multiplexed Paper-Based Vertical Flow Assay
Deep learning-enhanced dual-mode multiplexed optical sensor for point-of-care diagnostics of cardiovascular diseases
Advancing Diagnostics Through Science
Evora Diagnostics is committed to developing technologies grounded in rigorous research, clinical validation, and scientific innovation.